Name: Cetaxim IM/IV Injection 500 mg/10 ml
Brand: Cetaxim
SKU: cetaxim-im-iv-injection-500-mg-10-ml
Price: 50076 BDT
Availability: OnlineOnly

Introduction

Cetaxim IM/IV Injection 500 mg/10 ml is a third-generation cephalosporin antibiotic. Like other third-generation cephalosporins, it has broad spectrum activity against Gram positive and Gram negative bacteria. In most cases, it is considered to be equivalent to ceftriaxone in terms of safety and efficacy.

Uses

Cetaxim IM/IV Injection 500 mg/10 ml is a third generation cephalosporin used to treat susceptible Gram negative and Gram positive bacterial infections.

Used to treat gonorrhoea, meningitis, and severe infections including infections of the kidney (pyelonephritis) and urinary system. Also used before an operation to prevent infection after surgery.

Associated Conditions

Animal bite
Bacteremia
Bacterial Infections
Bacterial Peritonitis
Bacterial Pneumonia
Bacterial Sepsis
Bacterial Sinusitis
Bacterial Urinary Tract Infections
Bone and Joint Infections
CNS ventriculitis
Central Nervous System Infections
Community Acquired Pneumonia (CAP)
Endometritis
Gonococcal arthritis
Gonorrhea
Gynaecological infection
Intra-Abdominal Infections
Lower respiratory tract infection bacterial
Lyme Neuroborreliosis
Meningitis bacterial
Pelvic Inflammatory Disease (PID)
Pelvic cellulitis
Postoperative Infections
Skin and Subcutaneous Tissue Bacterial Infections

Pharmacodynamics

Cetaxim IM/IV Injection 500 mg/10 ml is a third generation intravenous cephalosporin antibiotic. It has broad spectrum activity against Gram positive and Gram negative bacteria. It does not have activity against Pseudomonas aeruginosa. Cetaxim IM/IV Injection 500 mg/10 ml works by inhibiting bacterial cell wall biosynthesis. A positive feature of cefotaxime is that it display a resistance to penicillinases and is useful to treat infections that are resistant to penicillin derivatives.

Mechanism of Action

The bactericidal activity of cefotaxime results from the inhibition of cell wall synthesis via affinity for penicillin-binding proteins (PBPs). Cetaxim IM/IV Injection 500 mg/10 ml shows high affinity for penicillin-binding proteins in the cell wall including PBP Ib and PBP III.

Absorption

Rapidly absorbed following intramuscular injection.

Route of Elimination

Approximately 20-36% of an intravenously administered dose of 14C-cefotaxime is excreted by the kidney as unchanged cefotaxime and 15-25% as the desacetyl derivative, the major metabolite.

Half Life

Approximately 1 hour.

Toxicity

Adverse effects following overdosage include nausea, vomiting, epigastric distress, diarrhea, and convulsions. Oral rat LD₅₀ is over 20,000 mg/kg while intravenous rat LD₅₀ is over 7,000 mg/kg.

Food Interactions

No interactions found.

Dosage

Adults: The recommended dosage for mild to moderate infections is 1 gm every 12 hourly. However, dosage may be varied according to the severity of infection, sensitivity of causative organisms and condition of the patient. In severe infections dosage may be increased up to 12 gm daily given in 3 or 4 divided doses. For infections caused by sensitive Pseudomonas spp. daily doses of greater than 6 gm will usually be required

Children: The usual dosage range is 100-150 mg/kg/day in 2 to 4 divided doses. However, in very severe infections doses of up to 200 mg/kg/day may be required.

Neonates: The recommended dosage is 50 mg/kg/day in 2 to 4 divided doses. In severe infections 150-200 mg/kg/day, in divided doses, have been given.

Dosage in gonorrhoea: 500 mg as a single dose.